JP7681316B2 - タウを認識する抗体 - Google Patents

タウを認識する抗体 Download PDF

Info

Publication number
JP7681316B2
JP7681316B2 JP2021569259A JP2021569259A JP7681316B2 JP 7681316 B2 JP7681316 B2 JP 7681316B2 JP 2021569259 A JP2021569259 A JP 2021569259A JP 2021569259 A JP2021569259 A JP 2021569259A JP 7681316 B2 JP7681316 B2 JP 7681316B2
Authority
JP
Japan
Prior art keywords
seq
variable region
chain variable
amino acid
occupied
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021569259A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022520672A5 (enExample
JP2022520672A (ja
Inventor
サード，フィリップ ジェームズ ドーラン
エス． ニジャル，ターロチャン
アレクサンダー，スヴェトラーナ
バブアー，ロビン
タム，ステファン，ジェッド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prothena Biosciences Ltd
Original Assignee
Neotope Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neotope Biosciences Ltd filed Critical Neotope Biosciences Ltd
Publication of JP2022520672A publication Critical patent/JP2022520672A/ja
Publication of JP2022520672A5 publication Critical patent/JP2022520672A5/ja
Priority to JP2024209068A priority Critical patent/JP7843068B2/ja
Application granted granted Critical
Publication of JP7681316B2 publication Critical patent/JP7681316B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7047—Fibrils-Filaments-Plaque formation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2021569259A 2019-02-08 2020-02-07 タウを認識する抗体 Active JP7681316B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024209068A JP7843068B2 (ja) 2019-02-08 2024-11-29 タウを認識する抗体

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962803334P 2019-02-08 2019-02-08
US62/803,334 2019-02-08
US201962813124P 2019-03-03 2019-03-03
US62/813,124 2019-03-03
US201962855434P 2019-05-31 2019-05-31
US62/855,434 2019-05-31
PCT/US2020/017357 WO2020163817A1 (en) 2019-02-08 2020-02-07 Antibodies recognizing tau

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024209068A Division JP7843068B2 (ja) 2019-02-08 2024-11-29 タウを認識する抗体

Publications (3)

Publication Number Publication Date
JP2022520672A JP2022520672A (ja) 2022-03-31
JP2022520672A5 JP2022520672A5 (enExample) 2023-02-15
JP7681316B2 true JP7681316B2 (ja) 2025-05-22

Family

ID=71947192

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021569259A Active JP7681316B2 (ja) 2019-02-08 2020-02-07 タウを認識する抗体
JP2024209068A Active JP7843068B2 (ja) 2019-02-08 2024-11-29 タウを認識する抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024209068A Active JP7843068B2 (ja) 2019-02-08 2024-11-29 タウを認識する抗体

Country Status (14)

Country Link
US (1) US20220275067A1 (enExample)
EP (1) EP3921343A4 (enExample)
JP (2) JP7681316B2 (enExample)
KR (1) KR20210125037A (enExample)
CN (2) CN113597431B (enExample)
AU (1) AU2020219374B2 (enExample)
BR (1) BR112021015501A2 (enExample)
CA (1) CA3128392A1 (enExample)
CO (1) CO2021011140A2 (enExample)
IL (1) IL285444A (enExample)
MX (1) MX2021009440A (enExample)
PE (1) PE20211709A1 (enExample)
SG (1) SG11202106717PA (enExample)
WO (1) WO2020163817A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025029046A (ja) * 2019-02-08 2025-03-05 プロセナ バイオサイエンシーズ リミテッド タウを認識する抗体

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014165271A2 (en) 2013-03-13 2014-10-09 Neotope Biosciences Limited Tau immunotherapy
US10906964B2 (en) 2016-05-02 2021-02-02 Prothena Biosciences Limited Antibodies recognizing tau
EP3452507B1 (en) 2016-05-02 2022-10-19 Prothena Biosciences Limited Tau immunotherapy
MX2018013384A (es) 2016-05-02 2019-02-28 Prothena Biosciences Ltd Anticuerpos que reconocen tau.
SG11201910066QA (en) 2017-05-02 2019-11-28 Prothena Biosciences Ltd Antibodies recognizing tau
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
US11911484B2 (en) 2018-08-02 2024-02-27 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US12370264B1 (en) 2018-08-02 2025-07-29 Dyne Therapeutics, Inc. Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
US12097263B2 (en) 2018-08-02 2024-09-24 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
TWI859197B (zh) 2019-03-03 2024-10-21 愛爾蘭商普羅帝納生物科學公司 識別ｔａｕ之抗體
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
US11633498B2 (en) 2021-07-09 2023-04-25 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
CA3226301A1 (en) * 2021-07-09 2023-01-12 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
IL316143A (en) 2022-04-15 2024-12-01 Dyne Therapeutics Inc Muscle targeting complexes and formulations for the treatment of myotonic dystrophy
CN117003872A (zh) * 2022-04-28 2023-11-07 北京天广实生物技术股份有限公司 含有突变轻链可变区骨架的单链抗体片段
JP2023175325A (ja) * 2022-05-30 2023-12-12 学校法人順天堂 タウオパチーの鑑別診断法
WO2025198916A1 (en) * 2024-03-16 2025-09-25 Abbvie Inc. Anti-tau antibodies

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003508788A (ja) 1999-09-09 2003-03-04 マックス−プランク−ゲゼルシャフト ツール フォルデルング デル ヴィッセンシャフテン エー．ファウ． ペアードヘリカルフィラメントの核形成のための最小タウペプチド
US20100204085A1 (en) 2009-02-06 2010-08-12 Eisenberg David S Structure-based design of peptide inhibitors of amyloid fibrillation
WO2012106363A2 (en) 2011-01-31 2012-08-09 Intellect Neurosciences Inc. Treatment of tauopathies
JP2014522643A (ja) 2011-07-04 2014-09-08 ノルディック・ビオサイエンス・エー／エス 神経変性状態の生化学的マーカー
JP2014530597A (ja) 2011-09-19 2014-11-20 アクソン ニューロサイエンス エスエー アルツハイマー病におけるタウ媒介性病理のタンパク質ベースの治療および診断

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102596236B (zh) * 2009-07-30 2015-06-24 辉瑞疫苗有限责任公司 抗原性Tau肽及其用途
WO2013059786A1 (en) * 2011-10-21 2013-04-25 The Ohio State University Methylated peptides derived from tau protein and their antibodies for diagnosis and therapy of alzheimer's disease
US9200068B2 (en) * 2012-12-18 2015-12-01 Regents Of The University Of Minnesota Compositions and methods related to tauopathy
WO2014165271A2 (en) * 2013-03-13 2014-10-09 Neotope Biosciences Limited Tau immunotherapy
US20150253341A1 (en) * 2014-02-10 2015-09-10 Merck Sharp & Dohme Corp. Quantification of tau in biological samples by immunoaffinity enrichment and mass spectrometry
NZ775762A (en) * 2015-06-05 2025-02-28 Genentech Inc Anti-tau antibodies and methods of use
JP7725185B2 (ja) * 2015-10-06 2025-08-19 アレクトル エルエルシー 抗ｔｒｅｍ２抗体及びその使用方法
US11319372B2 (en) * 2017-02-21 2022-05-03 Remd Biotherapeutics, Inc. Cancer treatment using antibodies that bind cytotoxic T-lymphocyte antigen-4 (CTLA-4)
SG11202106717PA (en) * 2019-02-08 2021-07-29 Prothena Biosciences Ltd Antibodies recognizing tau

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003508788A (ja) 1999-09-09 2003-03-04 マックス−プランク−ゲゼルシャフト ツール フォルデルング デル ヴィッセンシャフテン エー．ファウ． ペアードヘリカルフィラメントの核形成のための最小タウペプチド
US20100204085A1 (en) 2009-02-06 2010-08-12 Eisenberg David S Structure-based design of peptide inhibitors of amyloid fibrillation
WO2012106363A2 (en) 2011-01-31 2012-08-09 Intellect Neurosciences Inc. Treatment of tauopathies
JP2014522643A (ja) 2011-07-04 2014-09-08 ノルディック・ビオサイエンス・エー／エス 神経変性状態の生化学的マーカー
JP2014530597A (ja) 2011-09-19 2014-11-20 アクソン ニューロサイエンス エスエー アルツハイマー病におけるタウ媒介性病理のタンパク質ベースの治療および診断

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SCIENTIFIC REPORTS，2018年04月18日，8: 6209，p. 1-11

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025029046A (ja) * 2019-02-08 2025-03-05 プロセナ バイオサイエンシーズ リミテッド タウを認識する抗体
JP7843068B2 (ja) 2019-02-08 2026-04-09 プロセナ バイオサイエンシーズ リミテッド タウを認識する抗体

Also Published As

Publication number Publication date
CO2021011140A2 (es) 2021-09-20
BR112021015501A2 (pt) 2021-10-19
MX2021009440A (es) 2021-09-10
PE20211709A1 (es) 2021-09-01
JP7843068B2 (ja) 2026-04-09
EP3921343A4 (en) 2022-12-14
CN113597431B (zh) 2025-02-21
KR20210125037A (ko) 2021-10-15
EP3921343A1 (en) 2021-12-15
CA3128392A1 (en) 2020-08-13
WO2020163817A1 (en) 2020-08-13
IL285444A (en) 2021-09-30
CN113597431A (zh) 2021-11-02
JP2022520672A (ja) 2022-03-31
AU2020219374A1 (en) 2021-07-01
CN119954947A (zh) 2025-05-09
US20220275067A1 (en) 2022-09-01
JP2025029046A (ja) 2025-03-05
SG11202106717PA (en) 2021-07-29
AU2020219374B2 (en) 2026-07-02

Similar Documents

Publication Publication Date Title
JP7843068B2 (ja) タウを認識する抗体
US11584791B2 (en) Antibodies recognizing tau
JP7587304B2 (ja) タウ認識抗体
US20240209073A1 (en) Antibodies recognizing tau
US10906964B2 (en) Antibodies recognizing tau
AU2018448903B2 (en) Antibodies recognizing tau
HK40120191A (en) Antibodies recognizing tau
EA047155B1 (ru) Антитела, распознающие тау

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230207

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230207

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240416

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240730

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241129

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250415

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250501

R150 Certificate of patent or registration of utility model

Ref document number: 7681316

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150